Christopher Giordano has served as CEO and a director on the Tenax board since July 2021 and also as President of Tenax since October 2021. From early 2018 to 2021, he served as President of IQVIA Biotech and IQVIA MedTech, two full-service clinical research business units of IQVIA (formerly Quintiles) that provide comprehensive services to biotech, pharma, and device/diagnostic product development teams. Mr. Giordano’s team executed a clinical trial portfolio that grew from 250 to 400 active projects during his three years of leadership, and produced double-digit annual sales growth in this period. Mr. Giordano joined Quintiles in 2008 as Vice President, to oversee all consulting, regulatory, commercial, and clinical development services (including early-phase pharmacology through phase IV registry and safety studies) offered to his clients in the oncology, auto-immune, CNS, cardiovascular, and renal disease areas. From 2008-2013, he oversaw all the Phase III trials contributing to global approvals of a new oral anticoagulant (NOAC), leading to his appointments as Americas (2011), and then Global (2013) Vice President of the cardiovascular, renal, and metabolic therapeutic area at Quintiles. Mr. Giordano’s team executed over a dozen global CVOTs during this period in patients with heart, vascular, kidney, and metabolic diseases. From 2001-2008, Mr. Giordano served in sales and operational management roles at PPD, also a global clinical research organization, where his primary focus was biotechnology companies.
